Key facts
- It has raised $50.6M; the latest was Seed Round ($50.6M) in Apr 2025.
- Notable investors include General Catalyst, Endeavor Catalyst, Greylock, The General Partnership, Next Play Ventures — 11 tracked in total.
- Status: Privately Held (backing).
Leadership
- Jonathan BaellChief Scientific Officer
- Ujjwal SinghChief Technology Officer & Founder
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Manas AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Manas AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Manas AI
Developer of a full-stack, artificial intelligence-driven drug discovery platform designed to reduce drug development timelines. The company offers proprietary AI models, generative computational chemistry, and biology, enabling clients to streamline development and improve efficiency.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 8
- Website
- manasai.co/
- Ownership
- Privately Held (backing)
Manas AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Manas AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Manas AI in its N-PORT filings yet. We sweep new filings monthly.